Do Not Reduce the Dose – Stop Methimazole and Investigate
Diarrhea in a patient newly started on methimazole 20 mg should prompt immediate discontinuation of the medication and evaluation for serious adverse effects, not dose reduction. The patient must be assessed urgently for signs of hepatotoxicity, agranulocytosis, or other major adverse reactions before any decision about continuing antithyroid therapy 1, 2.
Why Dose Reduction is Not the Answer
The American Thyroid Association/American Association of Clinical Endocrinologists guidelines are explicit: patients should stop antithyroid drugs immediately and contact their physician when developing gastrointestinal symptoms including diarrhea, abdominal pain, or nausea 1, 2. These symptoms may herald serious complications:
Hepatotoxicity: Methimazole can cause cholestatic liver injury, with symptoms including abdominal pain, nausea, and diarrhea. The FDA label warns that drug treatment should be discontinued promptly if hepatic transaminases exceed 3 times the upper limit of normal 2.
Agranulocytosis: While typically presenting with fever and pharyngitis, systemic symptoms including gastrointestinal complaints can occur 2.
Immediate Clinical Actions Required
Stop methimazole immediately and perform the following assessments:
Liver function tests: Check bilirubin, alkaline phosphatase, ALT, and AST to rule out hepatotoxicity 1, 2
Complete blood count with differential: Evaluate for agranulocytosis or other hematologic complications 1
Clinical evaluation: Assess for fever, jaundice, dark urine, light-colored stools, right upper quadrant pain, or other warning signs 1, 2
Consider lactose intolerance: If the patient has known lactase deficiency, diarrhea may result from lactose carrier in the tablets rather than drug toxicity. This can be confirmed by temporal relationship and trial of lactose-free formulation 3
Important Caveats
The guidelines emphasize that minor side effects can be managed with concurrent antihistamine therapy without stopping the drug, but persistent symptoms require cessation 1. However, gastrointestinal symptoms—particularly when new-onset diarrhea occurs shortly after starting therapy—warrant a more cautious approach given the potential for serious hepatotoxicity.
Recent pharmacovigilance data confirms that most methimazole-related adverse events occur early, with a median onset of 27 days 4. Your patient fits this high-risk window.
After Safety Evaluation
If investigations rule out serious adverse effects and lactose intolerance is confirmed as the cause, switching to a lactose-free methimazole formulation at the same 20 mg dose is appropriate 3.
If hepatotoxicity or other serious reactions are confirmed, switching to the alternative antithyroid drug (propylthiouracil) is absolutely contraindicated due to cross-reactivity risk 1. The patient should be referred for radioactive iodine therapy or thyroidectomy 1.
The initial methimazole dose of 20 mg daily is appropriate for moderately severe hyperthyroidism and should not be reduced simply due to diarrhea without first excluding serious complications 1, 2.